MarketBeat
21 Sept 2026, 05:03 UTC · 2h ago
Verdict
Headline takes no side. We score HELP +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 2 new · 2 priced in
Cybin expects top-line Phase 3 data for its HLP003 depression drug during the fourth quarter of 2026.
Newoutlined during H.C. Wainwright conference on Sep 21
So whatPositive results within the next 3 months would significantly derisk the 2028 NDA filing target.
More positive than 99% of claims this week
The company targets a new drug application filing and potential approval for HLP003 in 2028.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newoutlined during H.C. Wainwright conference on Sep 21
So whatThis establishes a multi-year window before commercial revenue, implying a need for funding beyond 2027.
More positive than 76% of claims this week
As of June 30, Cybin had approximately $166 million on its balance sheet.
Priced indata as of June 30
So whatGiven the lead drug's 2028 approval target, this cash must cover at least 3 years of R&D.
More positive than 62% of claims this week
Cybin completed a Phase 2 signal-finding study for HLP004, a DMT program for generalized anxiety disorder, earlier in 2026.
Priced inreported as occurring earlier in 2026
So whatFinalizing the next trial design will provide a secondary catalyst to the HLP003 timeline.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company provided positive Phase 2 data and clear regulatory milestones for its lead depression program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
5d ago
—
HELP hasn't traded since this ran. Last close $12.37 (Sep 18); the reaction starts at the next open.
HELP chart →
